Sensex 26,392.38
161.19 (0.61%)
Nifty 8,001.95
53.00 (0.67%)
APPS  |  CONTACT US  |  CAREERS  |  LOCATE US  |  DOWNLOADS  |  BLOG
Financial Services | Broking & Distribution | Asset Management | Private Wealth Management | Home Finance | Private Equity | Institutional Equities | Investment Banking | Commodities
Broking & Distribution > Markets > Company Information > News

Aurobindo Pharma Ltd

BSE Code : 524804   |   NSE Symbol : AUROPHARMA   |   ISIN : INE406A01037
OVERVIEW INFORMATION FINANCIALS COMPANY NEWS CORPORATE ACTIONS
 
Aurobindo Pharma gets final approval for Entecavir Tablets, 0.5mg and 1mg   27-Aug-2015 | 12:51
Aurobindo Pharma has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Entecavir Tablets, 0.5mg and 1mg (ANDA 206217). The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Baraclude® Tablets, 0.5mg and 1mg, of Bristol-Myers Squibb.Entecavir Tablets are indicated for treatment of chronic...
Aurobindo Pharma receives final approval for Omeprazole Delayed-release Capsules  20-Aug-2015 | 13:40
Aurobindo Pharma announced that the company has received the finalapproval from the US Food & Drug Administration (USFDA) to manufacture and market Omeprazole Delayed-release Capsules USP, 10mg, 20mg and 40mg (ANDA 203270).The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Prilosec® Delayed-release Capsules, 10mg, 20mg and 40mg of AstraZ...
Aurobindo Pharma receives final approval for Ibandronate Sodium Injection  20-Aug-2015 | 13:21
Aurobindo Pharma announced that the company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Ibandronate Sodium Injection, 3mg/3mL (1mg/mL), (ANDA 205332).Ibandronate Sodium Injection, 3mg/3mL (1mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Boniva® Injection, 3mg/3mL (1mg/mL) of Hoffmann-La ...
Board of Aurobindo Pharma recommends dividend  12-Aug-2015 | 13:42
Aurobindo Pharma announced that the Board of Directors of the Company at its meeting held on 12 August 2015, inter alia, have recommended the dividend of Rs 0.5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.Powered by Capital Market - Live News...
Aurobindo Pharma to hold board meeting  31-Jul-2015 | 17:07
Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 12 August 2015, to consider the Un-Audited Financial Results of the Company for the quarter ended 30 June 2015 (Q1).Powered by Capital Market - Live News...
Aurobindo Pharma gets final approval for Esmolol Hydrochloride Injection  27-Jul-2015 | 15:31
Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Esmolol Hydrochloride Injection, 100mg/10mL (10mg/mL), (ANDA 205520).Esmolol Hydrochloride Injection, 100mg/10mL (10mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Brevibloc® Injection, 10mg/mL of Baxter Healthcare Corporation. ...
Aurobindo Pharma allots equity shares   22-Jul-2015 | 17:46
Aurobindo Pharma announced that the Securities Allotment Committee of the Board of Directors of the Company on 22 July 2015, has allotted 29,19,82,275 equity shares of Re. 1/- each to the shareholders of the Company who held the shares on the Record Date i.e., 21 July 2015 as Bonus shares in the ratio of 1:1.Consequent to the aforesaid allotment, the paid up equity share capital of the Company ...
Aurobindo Pharma receives final approval for Flecainide Acetate Tablets   10-Jul-2015 | 10:12
Aurobindo Pharma announced that the Company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Flecainide Acetate Tablets USP 50 mg, 100 mg and 150 mg (ANDA 202821). Aurobindo will commence shipping shortly.The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Tambocor® Tablets, 50 mg, 100 m...
Aurobindo Pharma receives final approval for Azithromycin for Injection USP, 500..  22-Jun-2015 | 10:53
Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Azithromycin forInjection USP, 500mg /vial (ANDA 203294).Azithromycin for Injection USP, 500mg /vial is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Zithromax® (Azithromycin for Injection) 500mg/vial of Pfizer, Inc. Azithromycin for in...
Aurobindo Pharma receives final approval for Entacapone Tablets USG, 200mg   22-Jun-2015 | 10:18
Aurobindo Pharma announce that the company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Entacapone Tablets USP, 200mg (ANDA 203437). The product will be launched soon.The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Comtan® Tablets 200mg of Orion Corporation. Entacapone Tablets a...
<< < 12> >> 
  Company Information :   Company List A-Z  |   Snapshot  |   Volume Chart  |   Investor Returns  |   Score Board  |   Company Peer Comparison  |   Background  |   Board of Directors  |   Quarterly Results  |   Balance Sheet  |   Share Holding Pattern  |   MF Holdings  |   Profit & Loss  |   Key Ratios / Cash Flow  |   Company News  |   Bonus / Split / Rights  |   Dividend / Book Closure  |   Capital Structure  |   Insider Trading History  |   Top Companies By MCAP  |   Top Dividend Yield  
  Equity Market       Derivatives       Mutual Funds       Commodities       Currencies       News       IPO    
Login
Login Open An Account Trade Now
7 day Free trial of our advice
High Speed Multi Asset trading - Orion Lite
Trading Insights
Trading Tool - Trade Guide Signal
Currency Daily Report
Financial Services Products & ServicesBusiness PartnerMarket InfoResearchQuick LinksBusinesses
Stocks   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Mutual Funds   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Commodities   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Disclaimer | Cookie Policy | Additional Disclaimer for U.S. Persons  | Feedback | Locate Us | Do Not Call Form
Motilal Oswal Securities Ltd. (MOSL) Member of NSE, BSE and MSEI
Regd Office: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; CIN no.: U65990MH1994PLC079418; Tel No.: 022 3980 4263
Correspondence Office Address: Motilal Oswal Securities Limited, Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West) Mumbai – 400064.; Tel No.: 022 3080 1000

Customer having any query / feedback / clarification may write to query@motilaloswal.com
In case of grievances for Securities Broking write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com, for Commodity Broking to commoditygrievances@motilaloswal.com


Registration Numbers: NSE (Cash) INB231041238; NSE (F&O): INF231041238; NSE (CD): INE231041238; BSE (Cash): INB011041257; BSE (F&O) INF011041257; BSE (CD); MSEI (Cash) : INB261041231; MSEI (F&O): INF261041231; MSEI (CD): INE261041231; CDSL: IN-DP-16-2015 & NSDL: IN-DP-NSDL-152-2000;SEBI Research Analyst: INH000000412; AMFI:ARN 17397. PMS: INP000000670 ; PMS & Mutual Funds are offered through Motilal Oswal Asset Management Company Ltd(MOAMC) which is group company of MOSL. PMS (INP000004409) is offered through Motilal Oswal Wealth Management Ltd. (MOWML) which is a group company of MOSL.  Motilal Oswal Commodities Broker Pvt. Ltd. (MOCBPL) member of MCX, NCDEX and NCDEX Spot. MCX Member ID 29500; NCDEX-NCEDX-CO-04-00114; NCDEX Spot Exchange Limited 10014. FMC Unique membership code: MCX: MCX/TCM/CORP/0725, NCDEX: NCDEX/TCM/CORP/0033, Commodity Services are offered through MOCBPL which a group company of Motilal Oswal Securities Ltd. Motilal Oswal Securities Ltd is a distributor of Mutual Fund & IPOs. Investment in Securities is subject to market risk.
Motilal Oswal Securities International Pvt Limited CRD-164319 SEC - 08-69093
Copyright © 2015 MOSL. All Rights Reserved. Market Data provided by C-MOTS Infotech (ISO 9001:2008 Certified)

Site best viewed in IE 7.0+, Mozila Firefox 3.0+ and Google Chrome at 1024 x 768 pixels resolution
GET QUOTES    RESEARCH REPORT  
Our research reports can be searched based on companies covered (COM), sectors covered (SEC) or report names (RPT). Type any three characters of your query to see a search list.